Riskpilot← Back to searchSign inGet full accessVERNIX PHARMA AS
ASActiveOrg 871587612Inkognitogata 35, 0256 OsloDevelopment of building projects · NACE 6812Est. 19940 employees
Revenue 2024
NOK 0
EBITDA margin
—
-15% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
NOK -15K
-15% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -15K | -15% |
| Net profit | NOK -15K | -15% |
| Total assets | NOK 185K | -7% |
| Equity | NOK 185K | -7% |
| Employees | 0 | — |
Legal name
VERNIX PHARMA AS
Org number
871587612
Legal form
Aksjeselskap
NACE code
6812 · Development of building projects
Founded
19. desember 1994
Share capital
NOK 243 400
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Forskning, utvikling, samt salg av kremer og andre farmasøytiske og medisinske produkter og det som naturlig hører hertil, herunder deltagelse og samarbeid med andre selskaper med lignende virksomhet.
Address
Inkognitogata 35, 0256 Oslo
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 993 | 0 | 1 455 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −381 | −526 | −730 | −385 | −150 | −825 | −298 | 1 835 | −25 | 1 406 | −21 | −22 | −18 | −18 | −7 | −13 | −15 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | −381 | −526 | −730 | −385 | −150 | −825 | −298 | 1 835 | −25 | 1 406 | −21 | −22 | −18 | −18 | −7 | −13 | −15 |
| Net financials | 112 | 44 | 29 | 3 | 1 | 9 | 1 | −0 | 2 | 1 | 0 | 0 | 0 | −0 | 0 | −0 | 0 |
| Profit before tax | −269 | −481 | −700 | −382 | −149 | −815 | −297 | 1 835 | −24 | 1 407 | −21 | −22 | −18 | −18 | −7 | −13 | −15 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −269 | −481 | −700 | −382 | −149 | −815 | −297 | 1 835 | −24 | 1 407 | −21 | −22 | −18 | −18 | −7 | −13 | −15 |
| Item | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1 796 | 1 315 | 615 | 235 | 77 | 262 | 81 | 1 810 | 422 | 1 684 | 273 | 256 | 238 | 119 | 113 | 200 | 185 |
| Equity | 1 716 | 1 235 | 535 | 153 | 4 | 188 | −109 | 1 726 | 242 | 299 | 278 | 256 | 238 | 220 | 212 | 200 | 185 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 80 | 80 | 80 | 82 | 74 | 74 | 190 | 83 | 179 | 1 385 | −5 | 0 | 0 | −101 | −99 | 0 | 0 |
| Total debt | 80 | 80 | 80 | 82 | 74 | 74 | 190 | 83 | 179 | 1 385 | −5 | 0 | 0 | −101 | −99 | 0 | 0 |
EBITDA margin
-1492700.0%
This company
15.8%
Market median
-9447568% vs market
20082024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20082024
Return on equity
-8.1%
This company
18.4%
Market median
-144% vs market
20082024
Net profit margin
-1492700.0%
This company
8.1%
Market median
-18428495% vs market
20082024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20082024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20082024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Brønnøysundsregistrene · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via Brønnøysundsregistrene · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via Brønnøysundsregistrene · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via Brønnøysundsregistrene · Period 2012-01-01 – 2012-12-31
- Annual report 2011Filed via Brønnøysundsregistrene · Period 2011-01-01 – 2011-12-31
- Annual report 2010Filed via Brønnøysundsregistrene · Period 2010-01-01 – 2010-12-31
- Annual report 2009Filed via Brønnøysundsregistrene · Period 2009-01-01 – 2009-12-31
- Annual report 2008Filed via Brønnøysundsregistrene · Period 2008-01-01 – 2008-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
FH Contact Person | Contact Person | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2006 | — | — | |
| Chairman | 2006 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Knut Haadem Ab | Company | 52.3% | 52.3% | 2024 |
Haadem Invest As | Company | 13.9% | 13.9% | 2024 |
Songa Investments As | Company | 11.7% | 11.7% | 2024 |
Intelco As | Company | 11.7% | 11.7% | 2024 |
| Individual | 4.1% | 4.1% | 2024 | |
| Individual | 3.5% | 3.5% | 2024 | |
Olsson, Annette Haadem | Company | 2.9% | 2.9% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VERNIX PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Finn Haadem | Contact Person | 0 companies |
| Øystein Erling Tvenge | Board of Directors | 0 companies |
| Knut Haadem | Chairman | 0 companies |